- Home
- HTD vs QURE Comparison
HTD vs QURE Comparison
Compare HTD & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTD
- QURE
- Stock Information
- Founded
- HTD 2004
- QURE 1998
- Country
- HTD United States
- QURE Netherlands
- Employees
- HTD N/A
- QURE N/A
- Industry
- HTD Finance Companies
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- HTD Finance
- QURE Health Care
- Exchange
- HTD Nasdaq
- QURE Nasdaq
- Market Cap
- HTD 780.2M
- QURE 860.8M
- IPO Year
- HTD N/A
- QURE 2007
- Fundamental
- Price
- HTD $22.52
- QURE $14.05
- Analyst Decision
- HTD
- QURE Strong Buy
- Analyst Count
- HTD 0
- QURE 8
- Target Price
- HTD N/A
- QURE $32.43
- AVG Volume (30 Days)
- HTD 92.3K
- QURE 1.3M
- Earning Date
- HTD 01-01-0001
- QURE 02-26-2025
- Dividend Yield
- HTD 8.59%
- QURE N/A
- EPS Growth
- HTD N/A
- QURE N/A
- EPS
- HTD N/A
- QURE N/A
- Revenue
- HTD N/A
- QURE $28,587,000.00
- Revenue This Year
- HTD N/A
- QURE $153.92
- Revenue Next Year
- HTD N/A
- QURE N/A
- P/E Ratio
- HTD N/A
- QURE N/A
- Revenue Growth
- HTD N/A
- QURE N/A
- 52 Week Low
- HTD $16.17
- QURE $3.73
- 52 Week High
- HTD $22.13
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- HTD 53.59
- QURE 48.03
- Support Level
- HTD $21.43
- QURE $13.04
- Resistance Level
- HTD $22.75
- QURE $14.32
- Average True Range (ATR)
- HTD 0.36
- QURE 1.09
- MACD
- HTD 0.07
- QURE -0.75
- Stochastic Oscillator
- HTD 82.20
- QURE 16.40
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.